{"eventGroups":[{"description":"Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo radiotherapy\n\nlaboratory biomarker analysis: Correlative studies","id":"EG000","otherNumAffected":28,"otherNumAtRisk":100,"seriousNumAffected":8,"seriousNumAtRisk":100,"title":"Arm I (Nonmyeloablative Conditioning With Fludarabine and TBI)"},{"description":"Patients undergo TBI on day 0. All patients then undergo allogeneic peripheral blood stem cell transplantation on day 0 and receive tacrolimus PO every 12 hours on days -3 to 180, with taper on day 56, or tacrolimus IV if unable to tolerate PO; and mycophenolate mofetil PO every 12 hours on days 0-27 or mycophenolate mofetil IV if unable to tolerate PO.\n\ntotal-body irradiation: Undergo radiotherapy\n\nmycophenolate mofetil: Given IV or PO\n\ntacrolimus: Given IV or PO\n\nperipheral blood stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplant\n\nnonmyeloablative allogeneic hematopoietic stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplant\n\nlaboratory biomarker analysis: Correlative studies","id":"EG001","otherNumAffected":17,"otherNumAtRisk":50,"seriousNumAffected":5,"seriousNumAtRisk":50,"title":"Arm II (Nonmyeloablative Conditioning With TBI)"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":100},{"groupId":"EG001","numAffected":15,"numAtRisk":50}],"term":"Increased Creatinine"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":100},{"groupId":"EG001","numAffected":1,"numAtRisk":50}],"term":"Hemolysis / Hemolytic Anemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Hepatobiliary disorders","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":100},{"groupId":"EG001","numAffected":3,"numAtRisk":50}],"term":"Hyperbilirubinemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":100},{"groupId":"EG001","numAffected":2,"numAtRisk":50}],"term":"Hypoxia / Hypoxemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Cardiac disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":100},{"groupId":"EG001","numAffected":4,"numAtRisk":50}],"term":"Hypotension"}],"seriousEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Cardiac disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":100},{"groupId":"EG001","numAffected":0,"numAtRisk":50}],"term":"Death, Renal Failure, Cardiac Failure"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Immune system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":100},{"groupId":"EG001","numAffected":0,"numAtRisk":50}],"term":"Death due to severe refractory autoimmune hemolytic anemia (present prior to transplant)"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Hepatobiliary disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":100},{"groupId":"EG001","numAffected":0,"numAtRisk":50}],"term":"Death, elevated bilirubin, fevers"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Eye disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":100},{"groupId":"EG001","numAffected":0,"numAtRisk":50}],"term":"Right central artery occlusion with right eye blindness"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Immune system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":100},{"groupId":"EG001","numAffected":0,"numAtRisk":50}],"term":"Severe abdominal pain due to gut GVHD and supravantricular arrhythmia/Atrial fibrillation"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":100},{"groupId":"EG001","numAffected":0,"numAtRisk":50}],"term":"Mental Status Change while on ativan, oxycodone, and flexeril"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":100},{"groupId":"EG001","numAffected":0,"numAtRisk":50}],"term":"Sepsis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Hepatobiliary disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":100},{"groupId":"EG001","numAffected":0,"numAtRisk":50}],"term":"Elevated LFT's with rising total bilirubin level"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Vascular disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":100},{"groupId":"EG001","numAffected":1,"numAtRisk":50}],"term":"Hypoxia and Hypotension"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":100},{"groupId":"EG001","numAffected":1,"numAtRisk":50}],"term":"Death, secondary to sepsis with multiorgan failure"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":100},{"groupId":"EG001","numAffected":1,"numAtRisk":50}],"term":"Perforated gastric ulcer"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":100},{"groupId":"EG001","numAffected":1,"numAtRisk":50}],"term":"Death due to adenovirus nephritis, sepsis, multifactorial renal failure"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Elevated creatinine level r/t acute renal failure in the setting of chronic kidney disease due to multiple myeloma","organSystem":"Renal and urinary disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":100},{"groupId":"EG001","numAffected":1,"numAtRisk":50}],"term":"Elevated creatinine level"}]}